Pharming (PHAR) EBIT Margin (2020 - 2026)
Pharming's (PHAR) quarterly EBIT Margin came in at 2.21% in Q2 2026, down 442.0% YoY from 0.65% in Q2 2025, and up 67.37% on a QoQ basis from 6.78% in Q1 2026.
Powered by 
Analysis
Pharming (PHAR) EBIT Margin (2020 - 2026) Analysis & Trends
Pharming (PHAR) has 7 years of EBIT Margin data on file, last reported at 2.21% in Q2 2026.
- Quarterly EBIT Margin fell 442.0% year-over-year to 2.21% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 5.02% (up 1416029032.0% YoY) and the FY2025 annual result came in at 6.87%, up 977.0% from the prior year.
- EBIT Margin grew to 2.21% in Q2 2026, from 6.78% in the prior quarter.
- In the past five years, EBIT Margin ranged from a high of 5481283422459.89% in Q3 2024 to a low of 7481662591687.04% in Q4 2024.
- A 5-year average of 111132176066.87% and a median of 1.1% in 2025 frame the typical range for EBIT Margin.
- Annual changes were most pronounced in 2024 — EBIT Margin tumbled 2000000000 bps — and 2025, when it jumped 2000000000 bps.
- Tracing PHAR's EBIT Margin over 5 years: stood at 18.81% in 2022, then sank by 143 bps to 8.0% in 2023, then slumped by 2000000000 bps to 7481662591687.04% in 2024, then soared by 100 bps to 5.82% in 2025, then tumbled by 138 bps to 2.21% in 2026.
- The last three EBIT Margin figures came in at 2.21% (Q2 2026), 6.78% (Q1 2026), and 5.82% (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.92 Bn | 131.07 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.55 Bn | 58.37 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.26 Bn | 53.13 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | - |
| 6 | BeOne Medicines | 39.98 Bn | 34.89 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.32 Bn | 32.01 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.42 Bn | 27.59 Bn | - | 19.75% |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn | -0.36% |
| 10 | Pharming | 781.07 Mn | 621.57 Mn | 141.47 Mn | -2.21% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -2.21% |
| Mar 31, 2026 | -6.77% |
| Dec 31, 2025 | 5.82% |
| Sep 30, 2025 | 16.24% |
| Mar 31, 2025 | -8.85% |
| Dec 31, 2024 | -7.48% |
| Sep 30, 2024 | 5.48% |
| Jun 30, 2024 | -26,225,371.12% |
| Mar 31, 2024 | -29.32% |
| Dec 31, 2023 | 1.35% |
| Sep 30, 2023 | 2.86% |
| Jun 30, 2023 | 9.65% |
| Mar 31, 2023 | -32.12% |
| Dec 31, 2022 | 18.81% |
| Sep 30, 2022 | 14.39% |
| Jun 30, 2022 | 35.53% |
| Mar 31, 2022 | 6.01% |
| Dec 31, 2021 | -15.69% |
| Sep 30, 2021 | -3.19% |
| Jun 30, 2021 | 21.86% |